ABBV-CLS-628 + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autosomal Dominant Polycystic Kidney Disease
Conditions
Autosomal Dominant Polycystic Kidney Disease
Trial Timeline
Jun 9, 2025 → Aug 1, 2029
NCT ID
NCT06902558About ABBV-CLS-628 + Placebo
ABBV-CLS-628 + Placebo is a phase 2 stage product being developed by AbbVie for Autosomal Dominant Polycystic Kidney Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06902558. Target conditions include Autosomal Dominant Polycystic Kidney Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06902558 | Phase 2 | Recruiting |
Competing Products
19 competing products in Autosomal Dominant Polycystic Kidney Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B | AstraZeneca | Phase 1 | 33 |
| Placebo + Everolimus | Novartis | Approved | 85 |
| Octreotide + Placebo | Novartis | Phase 2/3 | 65 |
| Everolimus + Calcineurin inhibitors maintenance | Novartis | Phase 3 | 77 |
| Bosutinib + Bosutinib + Placebo | Pfizer | Phase 2 | 51 |
| VX-407 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE | Vertex Pharmaceuticals | Phase 1 | 32 |
| VX-407 + Placebo + Midazolam + VX-407 | Vertex Pharmaceuticals | Phase 1 | 32 |
| VX-407 + Placebo | Vertex Pharmaceuticals | Phase 1 | 32 |
| Tesevatinib | Sanofi | Phase 1/2 | 40 |
| Tesevatinib + Placebo | Sanofi | Phase 2 | 51 |
| Venglustat + Placebo | Sanofi | Phase 2/3 | 64 |
| Bardoxolone methyl oral capsule + Placebo oral capsule | Biogen | Phase 3 | 74 |
| Lanreotide + saline | Ipsen | Phase 3 | 74 |
| KB105 | Krystal Biotech | Phase 2 | 49 |
| KB105 | Krystal Biotech | Phase 1/2 | 38 |
| Lixivaptan + Placebo | Centessa Pharmaceuticals | Phase 3 | 72 |
| GLPG2737 + Placebo | Galapagos | Phase 2 | 47 |
| QR-1123 | ProQR | Phase 1/2 | 33 |